Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Mylan Inc       US6285301072

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Mylan Inc. : Mylan Launches First Generic Version of Doryx® 150 mg

04/30/2012 | 02:20pm US/Eastern

PITTSBURGH, April 30, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg, following a favorable decision by the U.S. District Court for the District of New Jersey in a patent infringement lawsuit brought by Warner Chilcott. The Court held, after trial, that Mylan's product does not infringe the subject patent. Mylan is shipping product immediately.

Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg is the generic version of Mayne Pharma's Doryx(®) 150 mg product (marketed by Warner Chilcott), and is a tetracycline-class antimicrobial.

Doxycycline Hyclate DR Tablets, 150 mg, had U.S. sales of approximately $264.1 million for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

SOURCE Mylan Inc.

React to this article
Latest news on MYLAN INC
05:01a MYLAN NV : Launches Gilead Sciences' Sovaldi® Tablets in India
05/03DJMARKET SNAPSHOT : Media, Smaller Energy Cos. Provide Bulk Of Results As Earnings..
05/01DJDrug Maker Mylan Sues Law Firm Kirkland & Ellis
04/30DJTeva Raises Guidance as Generic-Medicine Segment Grows
04/30DJTeva Raises Guidance as Generic-Medicine Segment Grows
04/29 Perrigo rejects raised Mylan bid; Teva recommits to Mylan buy
04/29DJMylan Boosts Offer for Perrigo to $35.6 Billion -- 2nd Update
04/29 Exclusive - Perrigo expected to reject Mylan's latest offer
04/29DJMylan Boosts Offer for Perrigo to $35.6 Billion
04/29DJMylan Boosts Offer for Perrigo to $35.6 Billion--Update
Dynamic quotes  
ON
| OFF